← Leaderboards
John P Moore
Weill Medical College Of Cornell Univ
$51,152,802
Attributed
$51,152,802
Total exposure
24
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$114,323,713 · 29
By mechanism
P01$73,591,040 · 14
U19$17,141,798 · 8
R01$15,860,294 · 4
R37$7,029,301 · 1
R21$566,105 · 1
P51$135,175 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- Ronald G Crystal$80,684,359
- Shahin Rafii$35,903,626
- Kendall A Smith$14,630,665
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1Neutralizing AntibodyBaseDesignProgramsAnimalsPropertyEpitopesAntigensGlycoproteinsVirusVaccinesCellsHiv Envelope Protein Gp120AntibodiesIn VitroMedical SchoolsPrincipal InvestigatorImmune SystemResearch Project GrantsStructureComplexCleaved CellVariant
Grant awards (144)
Neutralization of primary HIV-1 viruses$500,527
R01 · FY2025 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,689,011
P01 · FY2024 · AI · contact PI
Project-003$1,300,343
P01 · FY2024 · AI · contact PI
Core-001$1,200,371
P01 · FY2024 · AI · contact PI
Project-002$1,188,297
P01 · FY2024 · AI · contact PI
Neutralization of primary HIV-1 viruses$500,527
R01 · FY2024 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,689,011
P01 · FY2023 · AI · contact PI
PROJECT 1: Design of native-like SOSIP trimers$1,217,315
P01 · FY2023 · AI · contact PI
Neutralization of primary HIV-1 viruses$500,527
R01 · FY2023 · AI · contact PI
Administrative Core$300,098
P01 · FY2023 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$4,149,892
P01 · FY2022 · AI · contact PI
PROJECT 1: Design of native-like SOSIP trimers$1,332,535
P01 · FY2022 · AI · contact PI
Neutralization of Primate Immunodeficiency Viruses$450,065
R01 · FY2022 · AI · contact PI
Administrative Core$415,319
P01 · FY2022 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,722,115
P01 · FY2021 · AI · contact PI
PROJECT 1: Design of native-like SOSIP trimers$1,047,229
P01 · FY2021 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$680,752
P01 · FY2021 · AI · contact PI
Neutralization of Primate Immunodeficiency Viruses$450,065
R01 · FY2021 · AI · contact PI
Administrative Core$317,006
P01 · FY2021 · AI · contact PI
PROJECT 1: Design of native-like SOSIP trimers$196,682
P01 · FY2021 · AI · contact PI
Administrative Core$18,721
P01 · FY2021 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,108,766
P01 · FY2020 · AI · contact PI
PROJECT 1: Design of native-like SOSIP trimers$888,056
P01 · FY2020 · AI · contact PI
Neutralization of Primate Immunodeficiency Viruses$273,001
R01 · FY2020 · AI · contact PI
Administrative Core$259,530
P01 · FY2020 · AI · contact PI
Neutralization of Primate Immunodeficiency Viruses$177,065
R01 · FY2020 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,100,000
P01 · FY2019 · AI · contact PI
Design of native-like SOSIP trimers$901,723
P01 · FY2019 · AI · contact PI
Neutralization of Primate Immunodeficiency Viruses$450,065
R01 · FY2019 · AI · contact PI
Administrative Support$300,024
P01 · FY2019 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,100,000
P01 · FY2018 · AI · contact PI
Design of native-like SOSIP trimers$849,067
P01 · FY2018 · AI · contact PI
Neutralization of Primate Immunodeficiency Viruses$450,065
R01 · FY2018 · AI · contact PI
Administrative Support$300,022
P01 · FY2018 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,099,999
P01 · FY2017 · AI · contact PI
Design of native-like SOSIP trimers$818,558
P01 · FY2017 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$373,948
R37 · FY2017 · AI · contact PI
Administrative Support$320,370
P01 · FY2017 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,981,157
P01 · FY2016 · AI · contact PI
Design of native-like SOSIP trimers$908,847
P01 · FY2016 · AI · contact PI
Administrative Support$729,484
P01 · FY2016 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$373,948
R37 · FY2016 · AI · contact PI
Cleaved, stabilized HIV-1 Env trimers for structural and vaccine studies$3,100,000
P01 · FY2015 · AI · contact PI
Design of native-like SOSIP trimers$782,769
P01 · FY2015 · AI · contact PI
Second Receptors for Primate Immunodeficiency Viruses$422,500
R01 · FY2015 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$373,948
R37 · FY2015 · AI · contact PI
Administrative Support$200,003
P01 · FY2015 · AI · contact PI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,524,995
P01 · FY2014 · AI · contact PI
Trimer Production and Immunogenicity Testing$993,090
P01 · FY2014 · AI · contact PI
HIV-1 Env Protein Design$654,141
P01 · FY2014 · AI · contact PI
Second Receptors for Primate Immunodeficiency Viruses$422,500
R01 · FY2014 · AI · contact PI
Administrative Core$378,968
P01 · FY2014 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$373,948
R37 · FY2014 · AI · contact PI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,524,997
P01 · FY2013 · AI · contact PI
Trimer Production and Immunogenicity Testing$966,147
P01 · FY2013 · AI · contact PI
HIV-1 Env Protein Design$486,162
P01 · FY2013 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$444,948
R37 · FY2013 · AI · contact PI
Second Receptors for Primate Immunodeficiency Viruses$397,150
R01 · FY2013 · AI · contact PI
Administrative Core$310,176
P01 · FY2013 · AI · contact PI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,524,997
P01 · FY2012 · AI · contact PI
Trimer Production and Immunogenicity Testing$966,147
P01 · FY2012 · AI · contact PI
HIV-1 Env Protein Design$486,162
P01 · FY2012 · AI · contact PI
Second Receptors for Primate Immunodeficiency Viruses$422,500
R01 · FY2012 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$414,092
R37 · FY2012 · AI · contact PI
Administrative Core$310,176
P01 · FY2012 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$286,787
U19 · FY2012 · AI · contact PI
Structure and Immunogenicity of Cleaved, Stabilized HIV-1 Envelope Trimers$2,600,751
P01 · FY2011 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$1,358,317
U19 · FY2011 · AI · contact PI
Second Receptors for Primate Immunodeficiency Viruses$422,500
R01 · FY2011 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$414,092
R37 · FY2011 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$170,902
U19 · FY2011 · AI · contact PI
Administrative Core$118,387
U19 · FY2011 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$1,615,720
U19 · FY2010 · AI · contact PI
HIV-1 Env Vaccine Design$740,006
P01 · FY2010 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$418,275
R37 · FY2010 · AI · contact PI
Second Receptors For Primate Immunodeficeincy Viruses$392,184
R01 · FY2010 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$203,256
U19 · FY2010 · AI · contact PI
Modified envelope glycoproteins for HIV-1 vaccine$126,699
R01 · FY2010 · AI · contact PI
Administrative Core$119,666
U19 · FY2010 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$1,345,525
U19 · FY2009 · AI · contact PI
HIV-1 Env Vaccine Design$727,026
P01 · FY2009 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$422,291
R37 · FY2009 · AI · contact PI
Second Receptors For Primate Immunodeficeincy Viruses$383,754
R01 · FY2009 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$169,222
U19 · FY2009 · AI · contact PI
Modified envelope glycoproteins for HIV-1 vaccine$126,699
R01 · FY2009 · AI · contact PI
Administrative Core$100,031
U19 · FY2009 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$3,261,941
U19 · FY2008 · AI · contact PI
Combining microbicides and vaccines to prevent HIV-1 sexual transmission$1,199,493
U19 · FY2008 · AI · contact PI
Second Receptors For Primate Immunodeficeincy Viruses$1,074,051
R01 · FY2008 · AI · contact PI
Viral Host And Combinational Influences on PRO 140$480,482
U19 · FY2008 · AI · contact PI
Neutralization of Primary HIV-1 Viruses$420,000
R37 · FY2008 · AI · contact PI
Modified Envelope Glycoproteins for HIV-1 Vaccine$324,695
R01 · FY2008 · AI · contact PI
A practical microbicide based on HIV-1 entry inhibitors$256,954
U19 · FY2008 · AI · contact PI
Administrative Core$148,523
U19 · FY2008 · AI · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$135,175
P51 · FY2008 · RR · contact PI
Second Receptors For Primate Immunodeficeincy Viruses$14,851
R01 · FY2008 · AI · contact PI
AFE inhibitor combinations as topical microbicides against HIV-1$1,281,125
U19 · FY2007 · AI · contact PI
Viral Host And Combinational Influences on PRO 140$433,785
U19 · FY2007 · AI · contact PI
Second Receptors For Primate Immunodeficeincy Viruses$404,262
R01 · FY2007 · AI · contact PI
NEUTRALIZATION OF PRIMARY HIV-1 VIRUSES$367,524
R37 · FY2007 · AI · contact PI
Modified Envelope Glycoproteins for HIV-1 Vaccine$321,342
R01 · FY2007 · AI · contact PI
CORE--INHIBITOR ACQUISITION, EVALUATION AND FORMULATION$234,862
U19 · FY2007 · AI · contact PI
AFE inhibitor combinations as topical microbicides against HIV-1$1,376,141
U19 · FY2006 · AI · contact PI
Viral Host And Combinational Influences on PRO 140$437,067
U19 · FY2006 · AI · contact PI
Second Receptors For Primate Immunodeficeincy Viruses$417,357
R01 · FY2006 · AI · contact PI
NEUTRALIZATION OF PRIMARY HIV-1 VIRUSES$378,501
R37 · FY2006 · AI · contact PI
Modified Envelope Glycoproteins for HIV-1 Vaccine$321,298
R01 · FY2006 · AI · contact PI
CORE--INHIBITOR ACQUISITION, EVALUATION AND FORMULATION$220,053
U19 · FY2006 · AI · contact PI
AFE inhibitor combinations as HIV1 topical microbicides$1,864,885
U19 · FY2005 · AI
SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSES$423,750
R01 · FY2005 · AI
NEUTRALIZATION OF PRIMARY HIV-1 VIRUSES$387,610
R37 · FY2005 · AI
Modified Envelope Glycoproteins for HIV-1 Vaccine$319,448
R01 · FY2005 · AI
CORE--INHIBITOR ACQUISITION, EVALUATION AND FORMULATION$217,819
U19 · FY2005 · AI
Viral Host And Combinational Influences on PRO 140$135,609
U19 · FY2005 · AI
ADMINISTRATIVE$105,246
U19 · FY2005 · AI
ENTRY INHIBITORS AS TOPICAL MICROBICIDES AGAINST HIV-1$1,404,410
P01 · FY2004 · AI
SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSES$423,750
R01 · FY2004 · AI
NEUTRALIZATION OF PRIMARY HIV-1 VIRUSES$387,610
R37 · FY2004 · AI
Modified Envelope Glycoproteins for HIV-1 Vaccine$327,143
R01 · FY2004 · AI
CHRYSTALLIZING DISULFIDE-STABILIZED HIV-1 ENV PROTEINS$274,365
R21 · FY2004 · AI
ENTRY INHIBITORS AS TOPICAL MICROBICIDES AGAINST HIV-1$1,364,201
P01 · FY2003 · AI
MODIFIED ENVELOPE GLYCOPROTEINS FOR HIV1 VACCINE$486,773
R01 · FY2003 · AI
SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSES$423,750
R01 · FY2003 · AI
NEUTRALIZATION OF PRIMARY HIV-1 VIRUSES$404,985
R37 · FY2003 · AI
CHRYSTALLIZING DISULFIDE-STABILIZED HIV-1 ENV PROTEINS$291,740
R21 · FY2003 · AI
ENTRY INHIBITORS AS TOPICAL MICROBICIDES AGAINST HIV-1$1,147,968
P01 · FY2002 · AI
MODIFIED ENVELOPE GLYCOPROTEINS FOR HIV1 VACCINE$472,597
R01 · FY2002 · AI
SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSES$423,750
R01 · FY2002 · AI
NEUTRALIZATION OF PRIMARY HIV1 VIRUSES$352,172
R37 · FY2002 · AI
ENTRY INHIBITORS AS TOPICAL MICROBICIDES AGAINST HIV-1$64,000
P01 · FY2002 · AI
Core--Fusion-inhibitor evaluation and formulation$0
P01 · FY2002 · AI
Core--Fusion-inhibitor evaluation and formulation$0
P01 · FY2002 · AI
ENTRY INHIBITORS AS TOPICAL MICROBICIDES AGAINST HIV-1$1,203,448
P01 · FY2001 · AI
MODIFIED ENVELOPE GLYCOPROTEINS FOR HIV1 VACCINE$660,192
R01 · FY2001 · AI
SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSES$402,563
R01 · FY2001 · AI
NEUTRALIZATION OF PRIMARY HIV1 VIRUSES$359,289
R37 · FY2001 · AI
HIV NEUTRALIZATION IN VITRO &IN SHIV-INFECTED MACAQUES$286,708
R01 · FY2001 · HL
Core--Fusion-inhibitor evaluation and formulation$0
P01 · FY2001 · AI
MODIFIED ENVELOPE GLYCOPROTEINS FOR HIV1 VACCINE$688,474
R01 · FY2000 · AI
SECOND RECEPTORS FOR PRIMATE IMMUNODEFICIENCY VIRUSES$430,828
R01 · FY2000 · AI
HIV NEUTRALIZATION IN VITRO &IN SHIV-INFECTED MACAQUES$304,083
R01 · FY2000 · HL
NEUTRALIZATION OF PRIMARY HIV1 VIRUSES$216,358
R37 · FY2000 · AI
NEUTRALIZATION OF PRIMARY HIV1 VIRUSES$145,762
R37 · FY2000 · AI
MODIFIED ENVELOPE GLYCOPROTEINS FOR HIV1 VACCINE$40,236
R01 · FY2000 · AI